ALTERING PHARMACOKINETICS OF PIRFENIDONE THERAPY

• US 20080287508A1
• Filed: 01/25/2008
• Published: 11/20/2008
• Est. Priority Date: 05/18/2007
• Status: Abandoned Application

• Current Assignee: Intermune Incorporated (Roche Holding AG)
• Original Assignee: Intermune Incorporated (Roche Holding AG)
• Inventors: Freemer, Michelle M., Loutit, Jeffery S., Robinson, Cynthia Y.
• Application Number:
  US12/020,068
• Publication Number:
  US 20080287508A1
• Time in Patent Office: Days
• US Class Current: 514/350
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/4418 having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/12 Keratolytics, e.g. wart or anti-corn preparations
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis

Abstract

The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.

Claims

1. A method of administering pirfenidone to a human patient in need thereof comprising

(a) orally administering to the patient (1) food and (2) a pharmaceutical composition comprising pirfenidone, at a total daily dose of 2403 mg pirfenidone, wherein the ratio of the mean maximum plasma concentration of pirfenidone when said pharmaceutical composition is administered to the patient under fed conditions (C_max(fed)) to the mean maximum plasma concentration of pirfenidone when said pharmaceutical composition is administered to said patient under fasted conditions (C_max(fasted)) is about 0.35 to about 0.7 and

(b) advising the patient that taking pirfenidone with food reduces the incidence of adverse events, other than nausea.

3. The method of claim 1, wherein the area under the curve of the absorption curve of pirfenidone when administered under fed conditions (AUC_fed) is at least about 80% of the area under the curve of the absorption curve of pirfenidone when administered under fasted conditions (AUC_fasted).

4. The method of claim 1, wherein the ratio of the mean absorption half life of pirfenidone when said pharmaceutical composition is administered to the patient under fed conditions (t_{1/2, abs(fed)}) to the mean absorption half life of pirfenidone when said pharmaceutical composition is administered to the patient under fasted conditions (t_{1/2, abs(fasted)}) is about 2.5 to about 3.5.

5. The method of claim 4, wherein the area under the curve of the absorption curve of pirfenidone when administered under fed conditions (AUC_fed) is at least about 80% of the area tinder the curve of the absorption curve of pirfenidone when administered under fasted conditions (AUC_fasted).

7. The method of claim 1, wherein the administration of the food is within one hour of the administration of the pirfenidone.

9. The method of claim 1, wherein the adverse event comprises one or more of dizziness, somnolence, or headaches.

2. (canceled)

6. (canceled)

8. (canceled)

10. A method of providing pirfenidone therapy to a human patient in need thereof comprising

(a) orally administering pirfenidone, at a total daily dose of 2403 mg, with food to reduce the of adverse events, and

(b) advising the patient that the mean maximum plasma concentration of pirfenidone when administered under fed conditions (C_max(fed)) is lower than the mean maximum plasma concentration of pirfenidone when administered under fasted conditions (C_max(fasted)), wherein the ratio of C_max(fed):

C_max(fasted) is about 0.35 to about 0.7.

11. The method of claim 10, wherein the area under the curve of the absorption curve of pirfenidone when administered under fed conditions (AUC_fed) is at least about 80% of the area under the curve of the absorption curve of pirfenidone when administered under fasted conditions (AUC_fasted).

12. The method of claim 10 further comprising advising the patient that the mean absorption half-life of pirfenidone under fed conditions (t_{1/2, abs(fed)}) is longer than the mean absorption half-life of pirfenidone under fasted conditions (t_{1/2, abs(fasted)}), wherein the ratio t_{1/2, abs(fed)}:

t_{1/2, abs(fasted)} is about 2.5 to about 3.5.

13. The method of claim 12, wherein the area under the curve of the absorption curve of pirfenidone when administered under fed conditions (AUC_fed) is at least about 80% of the area under the curve of the absorption curve of pirfenidone when administered under fasted conditions (AUC_fasted).

15. The method of claim 10, wherein the adverse event is one or more of dizziness, somnolence, or headaches.

14. (canceled)

16. (canceled)

17. A method of administering pirfenidone to a human patient in need thereof comprising

(a) orally administering to the patient (1) food and (2) a pharmaceutical composition comprising pirfenidone, at a total daily dose of 2400 mg pirfenidone, wherein the ratio of the mean maximum plasma concentration of pirfenidone when said pharmaceutical composition is administered to the patient under fed conditions (C_max(fed)) to the mean maximum plasma concentration of pirfenidone when said pharmaceutical composition is administered to said patient under fasted conditions (C_max(fasted)) is about 0.35 to about 0.7 and

(b) advising the patient that taking pirfenidone with food reduces incidence of adverse events, other than nausea.

18. A method of providing pirfenidone therapy to a human patient in need thereof comprising

(a) orally administering pirfenidone, at a total daily dose of 2400 mg, with Food to reduce the incidence of adverse events, and

(b) advising the patient that the mean maximum plasma concentration of pirfenidone when administered under fed conditions (C_max(fed)) is lower than the mean maximum plasma concentration of pirfenidone when administered under fasted conditions (C_max(fasted)), wherein the ratio of C_max(fed):

C_max(fasted) is about 0.35 to about 0.7.

19. A method of providing pirfenidone therapy to a human patient in need thereof comprising

(a) orally administering pirfenidone, at a total daily dose of 2400 mg or 2403 mg, with food to reduce the incidence of adverse events, other than nausea and

(b) advising the patient that administering pirfenidone under fed conditions results in reduced mean maximum plasma concentration of pirfenidone (C_max) compared to fasted conditions,

wherein the ratio of C_max under fed conditions divided by C_max under fasted conditions is about 0.35 to about 0.7.

20. A method of providing pirfenidone therapy to a human patient in need thereof comprising

(a) orally administering pirfenidone with food to reduce the incidence of dizziness, somnolence, or headaches and

(b) advising the patient that administering pirfenidone under fed conditions results in reduced mean maximum plasma concentration of pirfenidone (C_max) compared to fasted conditions,

wherein the ratio of C_max under fed conditions divided by C_max under fasted conditions is about 0.35 to about 0.7.